Liquidia had its Relative Strength (RS) Rating upgraded from 86 to 93 Monday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the best stocks typically have an RS Rating of over 80 at the beginning of a new price run.
Liquidia is trying to complete a consolidation with a 16.81 buy point. See if it can clear the breakout price in heavy trade.
The stock's relative strength line is in new high territory, a promising indicator ahead of a potential breakout.
Liquidia showed 0% earnings growth last quarter, while sales growth came in at -36%. The company is expected to report its latest results on or around May 8.
Liquidia earns the No. 120 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
